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Increasing evidence suggests that both types of diabetes mellitus (DM) lead to cardiac structural and functional changes. In this
study we investigated and compared functional characteristics and underlying subcellular pathological features in rat models of
type-1 and type-2 diabetic cardiomyopathy. Type-1 DM was induced by streptozotocin. For type-2 DM, Zucker Diabetic Fatty
(ZDF) rats were used. Left ventricular pressure-volume analysis was performed to assess cardiac function.Myocardial nitrotyrosine
immunohistochemistry, TUNEL assay, hematoxylin-eosin, and Masson’s trichrome staining were performed. mRNA and protein
expression were quantified by qRT-PCR and Western blot. Marked systolic dysfunction in type-1 DM was associated with severe
nitrooxidative stress, apoptosis, and fibrosis. These pathological features were less pronounced or absent, while cardiomyocyte
hypertrophy was comparable in type-2 DM, which was associated with unaltered systolic function and increased diastolic stiffness.
mRNA-expression of hypertrophy markers c-fos, c-jun, and 𝛽-MHC, as well as pro-apoptotic caspase-12, was elevated in type-
1, while it remained unaltered or only slightly increased in type-2 DM. Expression of the profibrotic TGF-𝛽
1
was upregulated in
type-1 and showed a decrease in type-2 DM. We compared type-1 and type-2 diabetic cardiomyopathy in standard rat models and
described an altered pattern of key pathophysiological features in the diabetic heart and corresponding functional consequences.
1. Introduction
Depending on its pathomechanism, diabetes can be classified
into two main types, namely, type-1 and type-2 diabetes
mellitus (DM). It is a well-known phenomenon that type-
2 diabetes, most common form of diabetes, is dominated
by hyperinsulinaemia, hyperglycaemia, and dyslipidaemia,
while type-1 diabetes, due to the autoimmune-mediated
destruction of the 𝛽 cells of the Langerhans islets in the
pancreas, is characterized by insulinopenia, hyperglycaemia,
and a largely unaffected lipid profile. Furthermore, the onset
of type-1 diabetes is acute, unlike that of type-2 diabetes,
which is characterized by a period of insulin resistance,
hyperinsulinaemia, and euglycaemia preceding the onset
of hyperglycaemia. Although increased atherosclerosis of
the coronary arteries is thought to be responsible for a major
portion of the mortality in diabetic patients, there is evidence
supporting the existence of diabetes-induced direct structural
and functional alterations at the level of the myocardium
[1]. The development of diabetic cardiomyopathy has been
described in both types of DM, also in the absence of
coronary artery disease and hypertension, and is suggested
to be a consequence of altered cellular metabolism of the
myocardium, which increases the risk of heart failure [2].
For decades, experimental studies on diabetic car-
diomyopathy were performed on streptozotocin- (STZ-)
induced type-1-diabetic rodents, the most widely used, “stan-
dard” animal model of DM. Nevertheless, the majority
of diabetic patients have type-2 diabetes with a different
pathophysiological background. Therefore a number of
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animal models of type-2 DM have been developed and
become object of intensive cardiovascular investigations
recent years [3–5].
Our research group previously provided a detailed hemo-
dynamic characterisation of rat models of type-1 (STZ-
induced) and type-2 (Zucker Diabetic Fatty rats) DM by
the sophisticated method of left ventricular (LV) pressure-
volume (P-V) analysis. Different characteristics of type-1
and type-2 diabetic cardiac dysfunction could be demon-
strated: decreased systolic performance and delayed relax-
ation, mainly in type-1 DM; accompanied by increased
diastolic stiffness of the heart, more remarkably in type-2 DM
[6].
The underlying pathophysiological features and subcellu-
lar mechanisms responsible for the development of diabetic
cardiomyopathy are not completely understood. Metabolic
abnormalities and overproduction of reactive oxygen and
nitrogen species may trigger various intracellular pathways
and alter myocardial expression of different genes. Increased
nitrooxidative stress, cardiomyocyte hypertrophy, profibrotic
signalling, and myocardial remodelling along with apoptotic
processes have been reported to play a critical role in the
development of cardiomyopathy in both types of DM [7–9].
To what extent these characteristic molecular and cellular
changes develop in type-1 versus type-2 DM and how they
correspond with the described differences in several aspects
of cardiac dysfunction also remain to be elucidated. There-
fore, in the present study we aimed at describing myocardial
histological and molecular changes which may be involved
in different characteristics of LV dysfunction in the well-
established rat models of type-1 and type-2 DM [6, 10].
2. Materials and Methods
2.1. Animals. Male 12-week-old Sprague-Dawley (SD;
Charles River, Sulzfeld, Germany), Zucker Diabetic Fatty
(ZDF), and ZDF lean rats (Charles River, Kingston, NY) were
housed in a room at 22 ± 2∘C under 12-h light/dark cycles.
Sprague-Dawley rats were fed a standard laboratory rat diet
and ZDF rats a diet of Purina 5008 as recommended by the
supplier and water ad libitum. The rats were acclimatized for
at least 1 week before the experiments. All animals received
humane care in compliance with the Principles of Laboratory
Animal Care formulated by the National Society for Medical
Research and the Guide for the Care and Use of Laboratory
Animals prepared by the Institute of Laboratory Animal
Resources and published by the National Institutes of Health
(NIH Publication no. 86-23, revised 1996). This investigation
was reviewed and approved by the appropriate institutional
review committee.
2.2. Rat Model of Type-1 DM. Type-1 DM was induced in
rats (𝑛 = 8) with a single injection of streptozotocin (STZ,
60mg/kg, i.p.) freshly dissolved in 0.1M citrate buffer, pH =
4.5. Vehicle-treated animals served as nondiabetic controls
(STZ control group, 𝑛 = 10). Seventy-two hours after
STZ injection, a drop of blood was collected from the tail
vein, and the blood glucose concentration was determined
using a digital blood glucose meter and test strips (Accu-
Chek Sensor, Roche, Mannheim, Germany). Animals with
a random blood glucose level of >15mM were considered
as diabetic and were included into the study (STZ-induced
diabetic group). According to the pathophysiology and dis-
ease characteristics of type-1 DM, based on literature data and
results of our previous studies, experiments on the rats were
performed 8 weeks after the confirmation of diabetes [6].
2.3. Rat Model of Type-2 DM. The ZDF rat is an inbred
rat model that through genetic mutation and a special
diet develops type-2 diabetes and related complications.
Homozygous recessive males (fa/fa) develop obesity, fasting
hyperglycemia, and type-2 diabetes (ZDF Diabetic group,
𝑛 = 8). Homozygous dominant (+/+) and heterozygous
(fa/+) lean genotypes remain normoglycemic (ZDF Lean
group, 𝑛 = 9). According to the pathophysiology and disease
characteristics of type-2 DM, based on literature data and
results of our previous studies, experiments on the rats were
performed at the age of 30–32 weeks [6].
2.4. Blood and Urine Glucose Measurements. Before the
hemodynamic measurements, blood samples were collected
from the tail vein. Urine samples were collected by punctua-
tion of the urine bladder after hemodynamic measurements
had been completed. Blood and urine glucose levels were
determined by a digital blood glucose meter and test strips
(Accu-Chek Sensor, Roche).
2.5. Hemodynamic Measurements. Rats were anesthetized
with a mixture of ketamine (100mg/kg) and xylazine
(3mg/kg) i.p., tracheotomized, and intubated to facilitate
breathing. The animals were placed on controlled heating
pads and core temperature measured via a rectal probe was
maintained at 37∘C. A polyethylene catheter was inserted
into the left external jugular vein for fluid administration.
A 2F microtip P-V catheter (SPR-838, Millar Instruments,
Houston, TX, USA) was inserted into the right carotid artery
and advanced into the ascending aorta. After stabilization
for 5min, arterial blood pressure was recorded. After that,
the catheter was advanced into the left ventricle under
pressure control. After stabilization for 5min, the signalswere
continuously recorded at a sampling rate of 1000/s using a
P-V conductance system (MPVS-400, Millar Instruments,
Houston, TX, USA), stored, and displayed on a personal
computer by the PowerLab Chart5 Software System (ADIn-
struments Inc., Colorado Springs, CO, USA). In addition, P-
V-loops at different preloads were registered by transiently
compressing the inferior caval vein (reducing preload) under
the diaphragm with a cotton-tipped applicator. With the help
of a special P-V analysis program (PVAN,Millar Instruments,
Houston, TX, USA) ejection fraction (EF) and the slope of
the LV end-systolic P-V relationship (ESPVR) (according to
the parabolic curvilinear model) were calculated as load-
dependent and -independent indices of LV contractility,
respectively. LV end-diastolic pressure (LVEDP) and the
slope of the LV end-diastolic P-V relationship (EDPVR) were
calculated as reliable indexes of LV stiffness [11].
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The in vivo and in vitro volume calibrations of the
conductance system were performed as described previously
[11].
2.6. Histopathology. Hearts were fixed in buffered paraform-
aldehyde solution (4%) and embedded in paraffin. Then,
5-𝜇m thick sections were placed on adhesive slides and
stained with hematoxylin-eosin and Masson’s trichrome.
Light microscopic examination was performed with a Zeiss
microscope (Axio Observer.Z1, Carl Zeiss, Jena, Germany)
and digital images were captured using an imaging software
(QCapture Pro 6.0, QImaging, Canada). The transverse
transnuclear widths of randomly selected cardiomyocytes
weremeasured after calibrating the system.Themean value of
100 LV cardiomyocytes represents each sample. The amount
of myocardial collagen was determined by semiquantita-
tive morphometry scoring of Masson’s trichrome-stained
sections by one blinded observer as follows: 0: absent,
1: slight, 2:moderate, and 3: intense.Themean value of twenty
randomly selected visual fields (magnification 400x) of free
LV wall represents each sample.
2.7. Terminal Deoxynucleotidyl Transferase-Mediated dUTP
Nick-End Labeling (TUNEL) Assay. The detection was car-
ried out using a commercial kit following the protocol
provided by the manufacturer (Chemicon International,
Temecula, CA, USA). Rehydrated sections were treated
with 20𝜇g/mL DNase-free Proteinase-K (Sigma-Aldrich,
Germany) to retrieve antigenic epitopes, followed by 3%
hydrogen peroxide to quench endogenous peroxidase activ-
ity. Free 3󸀠-OH termini were labeled with digoxigenin-dUTP
for 1 h at 37∘C utilizing a terminal deoxynucleotidyl trans-
ferase reaction mixture (Chemicon International, Temecula,
CA, USA). Incorporated digoxigenin-conjugated nucleotides
were detected using a horseradish peroxidase conjugated
anti-digoxigenin antibody and 3,3󸀠-diaminobenzidine. Sec-
tions were counterstained with Gill’s hematoxylin. Dehy-
drated sections were cleared in xylene, mounted with Per-
mount (Fischer Scientific, Germany), and coverslips were
applied. Based on the intensity and distribution of labelling,
semiquantitative histomorphological assessment was per-
formed using conventional microscopy. For assessment of
TUNEL-labeled cells, the number of TUNEL positive and
total cardiomyocyte nuclei was counted (four microscopic
examination fields characterizing each specimen), and an
average percent value was calculated. The evaluation was
conducted by an investigator blinded to the study groups.
Data were expressed as fold change to the mean value of the
corresponding nondiabetic control group.
2.8. Nitrotyrosine Immunohistochemical Staining. According
to previously describedmethods [12]we performed immuno-
histochemical staining for nitrotyrosine, a marker of nitroox-
idative stress. Semiquantitative histomorphological assess-
ment was performed based on the intensity and distribution
of labelling using conventional microscopy. After initially
evaluating all corresponding tissue sections (magnification
200x), the tissue section with the most intense labelling
signals was used as a reference for maximum labelling inten-
sity. Each specimen was characterized with the average of 4
adjacent fields. Nitrotyrosine levels were scored as follows:
0: complete absence of immunoreactivity, 1: weak area of
staining, 2: intermediate staining, and 3: extensive staining.
Using the Cell∧A software (Olympus Soft Imaging Solutions
GmbH, Germany), we measured the area of the objects in
each class in each field, assigned an area score (1 ≤ 10%
positive cells, 2 = 11–50% positive cells, 3 = 51–80% positive
cells, and 4 ≥ 80% positive cells), and calculated an average
score for the whole picture (intensity score multiplied by area
score, 0–12).The evaluation was conducted by an investigator
blinded to the experimental groups.
2.9.Quantitative Real TimePolymeraseChainReaction (PCR).
Total RNA was extracted from LV myocardial samples
using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
RNA concentration and purity were determined photomet-
rically (260, 280, and 230 nm). Reverse transcription was
performed with the QuantiTect Reverse Transcription Kit
(Qiagen, Hilden, Germany) using 400 ng RNA in a volume
of 20𝜇L. Quantitative real-time PCRs were performed on
the StepOnePlus Real-Time PCR System with TaqMan Uni-
versal PCR MasterMix and TaqMan Gene Expression Assays
(AppliedBiosystems, FosterCity,USA) in case of endogenous
antioxidant genes, or on the LightCycler480 system with the
LightCycler480 Probes Master and Universal Probe Library
(UPL) probes (Roche, Mannheim, Germany) in case of all
other genes. Efficiency of the PCR reaction was confirmed
with standard curve analysis. Sample quantifications were
normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression in case of endogenous antioxidants and
to 𝛽-actin expression in case of all other genes by using
a pool of all cDNAs from the control groups (positive cali-
brator). Identification numbers of TaqMan Gene Expression
Assays (endogenous antioxidant gene targets) as well as UPL
probes and sequences of primers used (TIB Molbiol, Berlin,
Germany) (all other gene targets) are represented in Table 1.
Evaluation was performed with the StepOne Software 2.2.2
(Applied Biosystems, Foster City, USA) and LightCycler 480
SW 1.5 software (Roche, Mannheim, Germany), respectively.
2.10. Western Blot. Myocardial proteins were extracted into
a solution containing 8M urea, 5mM EDTA, 0.002% Tra-
sylol, 0.05mM PMSF, 0.003% Triton X-100 containing
protease inhibitors (Roche, Mannheim, Germany). Pro-
tein concentration was determined by a commercial kit
according to the manufacturer’s protocol (BCA protein
assay kit; Thermo Scientific, Rockford, USA). Total protein
homogenates (30 𝜇g) were denatured, separated on SDS-
PAGE gradient gels (Invitrogen, Darmstadt, Germany), and
transferred to PVDF membrane (Invitrogen, Darmstadt,
Germany). The blots were probed with an antibody specific
to TGF-𝛽
1
(1 : 1000, Santa Cruz Biotechnology, Heidelberg,
Germany). The immunoreactive protein bands were devel-
oped using EnhancedChemiluminescence system (ECLPlus,
PerkinElmer, Rodgau-Juegesheim, Germany) and measured
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Table 1: Identification numbers of TaqMan Gene Expression Assays and sequence for the forward (F) and reverse (R) primers (from 5󸀠 to 3󸀠)
and Universal Probe Library (UPL) probes used in quantitative real time PCR.
Gene target TaqMan Gene Expression Assay ID
Catalase Rn00560930 m1
GAPDH Rn01775763 g1
GSR Rn01482159 m1
SOD2 Rn00690587 g1
Thioredoxin Rn00587437 m1
Gene target Primer sequence UPL probes
ANF F: 5
󸀠-CAACACAGATCTGATGGATTTCA-3󸀠
R: 5󸀠-CGCTTCATCGGTCTGCTC-3󸀠 65
𝛼-MHC F: 5
󸀠-GGAGGTGGAGAAGCTGGAA-3󸀠
R: 5󸀠-ATCTTGCCCTCCTCATGCT-3󸀠 65
𝛽-actin F: 5
󸀠-CTAAGGCCAACCGTGAAAAG-3󸀠
R: 5󸀠-TACATGGCTGGGGTGTTGA-3󸀠 115
𝛽-MHC F: 5
󸀠-GCTGCAGAAGAAGCTCAAAGA-3󸀠
R: 5󸀠-GCAGCTTCTCCACCTTGG-3󸀠 65
Caspase-12 F: 5
󸀠-TGGATACTCAGTGGTGATAAAGGA-3󸀠
R: 5󸀠-ACGGCCAGCAAACTTCATTA-3󸀠 94
Collagen-1 F: 5
󸀠-CTGGCAACCTCAAGAAGTCC-3󸀠
R: 5󸀠-CAAGTTCCGGTGTGACTCG-3󸀠 65
Collagen-3 F: 5
󸀠-CCTGTTGGTCCATCTGGAAA-3󸀠
R: 5󸀠-GACCTTGGGGACCAGGAG-3󸀠 82
c-fos F: 5
󸀠-CCTGCAAGATCCCCAATG-3󸀠
R: 5󸀠-AGTCAAGTCCAGGGAGGTCA-3󸀠 115
c-jun F: 5
󸀠-TACCGGCCAGCAACT TTC-3󸀠
R: 5󸀠-TAGGCGCAGAAGAGGTTTTG-3󸀠 115
eNOS F: 5
󸀠-TGACCCTCACCGATACAACA-3󸀠
R: 5󸀠-CGGGTGTCTAGATCCATGC-3󸀠 5
ET-1 F: 5
󸀠-TGTCTACTTCTGCCACCTGGA-3󸀠
R: 5󸀠-CCTAGTCCATACGGGACGAC-3󸀠 115
GAPDH F: 5
󸀠-AGCTGGTCATCAATGGGAAA-3󸀠
R: 5󸀠-CGGCAGGTCCTTCTCTATCA-3󸀠 9
SOD1 F: 5
󸀠-GGTCCAGCGGATGAAGAG-3󸀠
R: 5󸀠-GGACACATTGGCCACACC-3󸀠 5
Atrial natriuretic factor (ANF), alpha-myosin heavy chain (𝛼-MHC), beta-myosin heavy chain (𝛽-MHC), endothelial nitric oxide synthase (eNOS), endothelin-
1 (ET-1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), glutathione reductase (GSR), and superoxide dismutase 1 (SOD1) and 2 (SOD2).
by an imaging densitometer with image analysis software
(Image J. NIH, Bethesda, MD, USA). Densitometric data
of each sample was normalized to the mean value of the
corresponding nondiabetic control group.
2.11. Statistical Analysis. All data are expressed as means ±
standard error of the mean (SEM). An unpaired two-sided
Student’s t-test was used to compare parameters of diabetic
and control rats in both models. A value of 𝑃 < 0.05 was
considered statistically significant.
3. Results
3.1. Heart Weight, Body Weight, and Glucose Levels. Com-
pared with the corresponding control group, DM was asso-
ciated with decreased body weight and increased blood
and urine glucose levels in both models (Table 2). Blood
glucose levels did not significantly differ between the two
diabetic groups. Heart weight to body weight ratio showed
a marked tendency towards increased values in the diabetic
animals of the type-2 DMmodel, while it reached a statistical
significance in the type-1 DMmodel (Table 2).
3.2. Cardiac Contractility and Ventricular Stiffness. Mean
arterial pressure did not significantly differ between diabetic
rats and corresponding controls (data not shown). P-V
loop derived load-dependent and -independent contractility
parameters (EF and slope of ESPVR) were significantly lower
in STZ-induced diabetic animals compared to nondiabetic
controls, suggesting impaired systolic performance in type-
1 DM. In contrast, compared with the corresponding control,
type-2 diabetic ZDF rats showed unaltered LV contractility
(Figure 1(a)).
LVEDP and the slope of EDPVR were significantly
increased in diabetic animals of the type-2 DM model,
indicating a marked increase in end-diastolic stiffness. These
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Table 2: Blood and urine glucose, body weight, and heart weight to body weight ratio.
Control SD STZ-diabetic SD ZDF lean ZDF diabetic
Blood glucose (mmol/L) 6.54 ± 0.16 26.08 ± 0.87∗ 6.28 ± 0.29 25.99 ± 2.08∗
Urine glucose (qualitative) Negative Positive Negative Positive
Body weight (g) 431.3 ± 5.9 330.0 ± 10.5∗ 440.0 ± 4.8 353.3 ± 9.5∗
HW/BW (g/kg) 2.92 ± 0.06 3.51 ± 0.14∗ 3.46 ± 0.05 3.74 ± 0.23
Blood and urine glucose, body weight, and heart weight to body weight ratio (HW/BW) values are shown in the groups of control Sprague-Dawley (SD),
streptozotocin- (STZ-) diabetic SD, ZDF lean, and ZDF diabetic rats. Values are means ± SEM. ∗𝑃 < 0.05 versus corresponding nondiabetic group.
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Figure 1: Different characteristics of cardiac dysfunction in type-1 and type-2 diabetes mellitus (DM) models. Left ventricular contractility
indices (a): slope of end systolic pressure-volume relationship (ESPVR) and ejection fraction (EF) in the groups of SD control, STZ-induced
diabetic SD, ZDF lean and ZDF diabetic rats. Parameters of left ventricular stiffness (b): slope of end-diastolic pressure-volume relationship
(EDPVR) and end-diastolic pressure (LVEDP) in the groups of SD control, STZ-induced diabetic SD, Zucker Diabetic Fatty (ZDF) lean and
ZDF diabetic rats. Bar graphs represent mean ± SEM. Percent changes between diabetic and corresponding nondiabetic control groups are
indicated in both DMmodels. ∗: 𝑃 < 0.05 versus the corresponding nondiabetic group.
changes could be observed only to a lower extent in type-1
diabetic rats (Figure 1(b)).
3.3. Histopathology. Thecharacteristics of diabetic cardiomy-
opathy were found in LV sections of the diabetic groups
with hematoxylin-eosin staining (Figure 2(a)). Disarray and
collapse of myofibers and myocardial degeneration could be
observed in the LVmyocardium of diabetic rats in bothmod-
els. Mean cardiomyocyte width, as a marker of cardiomy-
ocyte hypertrophy was significantly increased in both dia-
betic groups when compared to the corresponding controls
(Figure 3(a)).
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(a) HE
(b) TUNEL
(c) Nitrotyrosine
(d) Masson’s trichrome
Figure 2: Characteristic histopathological changes of the myocardium in type-1 and type-2 diabetes mellitus (DM) models. Representative
images of conventional histopathological examination (hematoxylin-eosin (HE) staining; scale bar: 50 𝜇m, (a)), TUNEL staining for DNA
breaks and apoptosis (brown cell nuclei, scale bar: 50𝜇m, (b)), immunohistochemistry for the nitrooxidative stress marker nitrotyrosine
(brown staining, scale bar: 50 𝜇m, (c)) and Masson’s trichrome staining for fibrosis detection (blue staining, scale bar: 60 𝜇m, (d)) of left
ventricular myocardium in the groups of SD control, streptozotocin- (STZ-) induced diabetic SD, ZDF lean and ZDF diabetic rats.
3.4. DNA Strand Breaks and Nitrooxidative Stress. Com-
pared with the corresponding controls, diabetic hearts were
associated with increased density of TUNEL-positive nuclei,
indicating DNA fragmentation (Figures 2(b) and 3(b)) and
increased immunoreactivity against the nitrooxidative stress
marker nitrotyrosine, as evidenced by increased brown stain-
ing (Figure 2(c)). Moreover, both TUNEL positivity and
nitrooxidative stress were found to be more pronounced
in type-1 when compared with the type-2 DM group
(Figure 3(c)).
Quantitative real-time PCR from LV myocardial RNA
extracts revealed that mRNA-expression for endogenous
antioxidants cytosolic superoxide dismutase 1 (SOD1),
catalase, glutathione reductase (GSR), and thioredoxin
was significantly upregulated in type-1 DM, while these
changes were less pronounced or absent in the type-2 DM
model. mRNA expression for the mitochondrial superoxide
dismutase 2 (SOD2) was not altered in any groups studied.
(Figure 4).
3.5. Myocardial Fibrosis. Myocardial fibrotic remodelling,
as reflected by Masson’s trichrome staining of myocardial
sections, was significantly more pronounced in the type-
1 DM model, when compared to type-2 DM (Figure 2(d)).
Semiquantitative scoring of the staining showed a marked
difference in LV fibrosis between the two diabetic models
(Figure 3(d)).
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Figure 3: Quantification of histopathological changes of the myocardium in type-1 and type-2 diabetes mellitus (DM) models. Mean
cardiomyocyte width asmarker of myocardial hypertrophy (a), fold change in the number of TUNEL-positive/total cardiomyocyte nuclei (b),
semiquantitative histomorphological scoring of nitrotyrosine immunostaining (c), andMasson’s trichrome fibrosis staining (d) in the groups
of SD control, streptozotocin- (STZ-) induced diabetic SD, Zucker Diabetic Fatty (ZDF) lean, and ZDF diabetic rats. Bar graphs represent
mean ± SEM. Percent changes between diabetic and corresponding nondiabetic control groups are indicated in both DMmodels. ∗: 𝑃 < 0.05
versus the corresponding nondiabetic group.
3.6. Myocardial Expression of Genes Involved in the Devel-
opment of Diabetic Cardiomyopathy. Quantitative real-time
PCR from LVmyocardial RNA extracts revealed that mRNA
expression for 𝛼-myosin heavy chain (𝛼-MHC) was signifi-
cantly decreased whereas 𝛽-MHC and endothelin-1 mRNA-
levels were increased in both diabetic groups compared to
corresponding controls (Figure 4). Whereas c-fos, c-jun, and
caspase-12 mRNA-expression was significantly upregulated,
collagen-1, collagen-3, and endothelial NOS mRNA-levels
were downregulated only in type-1 DMwhen compared with
the control group (Figure 4). Atrial natriuretic factor (ANF)
mRNA expression was upregulated in both types of DM, but
the change reached the level of statistical significance only
in the type-2 model (Figure 4). The gene expression changes
for 𝛼-MHC, 𝛽-MHC, c-fos, c-jun, caspase-12, collagen-1,
collagen-3, and endothelial NOS were significantly more
pronounced in type-1 when compared to the type-2 DM
group (Figure 4).
3.7. Western Blot Analysis of TGF-𝛽
1
. In Western blots, we
detected TGF-𝛽
1
protein in rat myocardium as a single band
at 25 kDa. Densitometric analysis of the bands revealed a
significant increase in relative TGF-𝛽
1
protein content in
myocardium from type-1 diabetic rats in comparisonwith the
corresponding controls. In contrast, significantly decreased
TGF-𝛽
1
protein expression could be detected in the type-2
DMmodel (Figure 5).
4. Discussion
In this study, a comparative investigation of functional,
histological, and molecular changes in the heart of type-
1 and type-2 diabetic rats was performed. The reported
differences in cardiac performance between the two dia-
betes models were accompanied by an altered pattern of
myocardial gene and protein expression and markers of
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Figure 4: Characteristic changes in myocardial expression of genes involved in the development of diabetic cardiomyopathy (a) and genes
of endogenous antioxidants (b) in type-1 and type-2 diabetes mellitus (DM) models. Relative mRNA expression for (a) hypertrophy markers
𝛼 myosin heavy chain (MHC), 𝛽-MHC, early genes of the hypertrophic transcriptional program c-fos and c-jun; extracellular matrix
components collagens 1 and 3, vascular endothelial marker endothelial nitric oxide synthase (eNOS) and endothelin-1 (ET-1); atrial natriuretic
factor (ANF) and proapoptotic caspase-12, as well as for (b) endogenous antioxidants superoxide dismutase 1 (SOD1) and 2 (SOD2), catalase,
glutathione reductase and thioredoxin in the groups of SD control, streptozotocin- (STZ-) induced diabetic SD, Zucker Diabetic Fatty (ZDF)
lean and ZDF diabetic rats. Bar graphs represent mean ± SEM. Percent changes between diabetic and corresponding nondiabetic control
groups are indicated in both DMmodels. ∗: 𝑃 < 0.05 versus the corresponding nondiabetic group.
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Figure 5: Changes of the myocardial protein expression of transforming growth factor (TGF)-𝛽
1
in type-1 and type-2 diabetes mellitus
(DM) models. Representative immunoblot analysis for the profibrotic mediator transforming growth factor (TGF)-𝛽
1
from left ventricular
myocardium (a) and relative myocardial TGF-𝛽
1
protein band densities (b) in the groups of SD control, streptozotocin- (STZ-) induced
diabetic SD, Zucker Diabetic Fatty (ZDF) lean, and ZDF diabetic rats. Bar graphs represent mean ± SEM. Percent changes between diabetic
and corresponding nondiabetic control groups are indicated in both DMmodels. ∗: 𝑃 < 0.05 versus the corresponding nondiabetic group.
nitrooxidative stress, apoptosis, cardiomyocyte hypertrophy,
and fibrotic remodelling of the myocardium. This is the first
study reporting characteristic differences on the cellular and
subcellular level between rat models of type-1 and type-2
diabetic cardiomyopathy.
In spite of the clinical importance of diabetic cardiomy-
opathy as a distinct disease entity, the cellular and molecular
pathomechanisms triggering the adverse changes in diabetic
myocardial structure and function have not been completely
understood. Oxidative imbalance and increased nitrooxida-
tive stress, cardiomyocyte apoptosis, and hypertrophy, as well
as myocardial fibrosis, have been suggested to be the key
pathophysiological features of development and progression
of diabetic cardiac complications [9].
Immunohistochemical staining against nitrotyrosine
(NT), a marker for nitrooxidative stress, clearly showed
increased NT-immunoreactivity in the diabetic myocardium
in both diabetes models, which is in line with previous
data [13, 14]. According to the semiquantitative analysis of
the staining, more pronounced nitrooxidative stress could
be documented in the type-1 DM model, when compared
with type-2 DM. The compensatory overexpression of
endogenous antioxidant systems (such as the SOD-catalase
and glutathione systems or thioredoxin) further confirmed
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a more significant increase of nitrooxidative stress in the
myocardium of our type-1 diabetic animals when compared
with type-2 DM. Increased nitrooxidative stress can result in
triggering pathways of apoptosis, ventricular hypertrophy,
and fibrotic remodelling [9].
Dysregulation of apoptosis, a programmed form of cell
death, is implicated in several cardiovascular pathologies,
including diabetic cardiomyopathy. Increasing body of evi-
dence from both clinical and experimental observations
suggests that progressive loss of cardiomyocytes via apoptosis
plays an important causal role in the development of diabetic
cardiomyopathy [8, 9, 15]. Increased cardiomyocyte apoptosis
is involved in the process of transition from compensated to
decompensated ventricular dysfunction in the diabetic heart
[16] as dead cardiomyocytes are replaced by extracellular
matrix components, which leads to the development of
collagen deposition and myocardial fibrosis [17, 18]. TUNEL
assay is a widely used method for assessing DNA breaks and
DNA fragmentation in various cells and thus it has been pro-
posed for detection of cells undergoing apoptosis [19]. Our
current results regarding TUNEL-positive cardiomyocyte
nuclei (Figures 2 and 3(b)) as well as myocardial expression
of the proapoptotic mediator caspase-12 (Figure 4) show
increased DNA fragmentation and cardiomyocyte apoptosis
in diabetic animals, more remarkably in the type-1 DM
model. Correspondingly, previous studies reported diabetes-
associated increase in TUNEL positive cardiomyocyte cell
nuclei both in type-1 [15] and type-2 diabetic rats [20], but
a direct comparison of the two DMmodels was not available
yet.
Several markers of myocardial hypertrophy have been
investigated in our study. Cardiomyocyte width showed a
significant increase in diabetic rats which was comparable in
both models (Figure 3(a)). An increasing tendency in heart
weight/body weight ratio was observed in type-2 diabetic
rats, which reached the level of statistical significance only
in the type-1 DM model; however, this index is severely
influenced by marked body weight changes (that were more
pronounced in the type-1 DMmodel).
Molecular mechanisms of the hypertrophic transcrip-
tional program include the transient activation of immediate-
early genes that encode transcription factors such as c-
jun and c-fos [21, 22]. These early genes were significantly
upregulated only in type-1 DM (Figure 4). c-jun and c-
fos have been described to activate the fetal gene program
(transcription of genes such as 𝛽-MHC or ANF), which
play a key role in adaptive hypertrophy and also in mal-
adaptive changes of cardiomyocytes, and have been widely
used as markers of pathological hypertrophy [23]. Decreased
expression of 𝛼-MHC and increase in the fetal type 𝛽-
MHC, as molecular markers of pathological hypertrophy,
were present in both DM models, being more prominent
in type-1 DM (Figure 4). The rate of myocardial overex-
pression of the hypertrophy marker ANF was found to
be comparable in the two DM models (Figure 4). These
results clearly reflect the existence of myocardial hypertro-
phy associated with diabetes in type-1 and also in type-2
DM models and are in correspondence with previous data
[9, 24, 25].
Fibrotic remodelling of the myocardium has been
reported to be another key pathophysiological feature in
diabetic cardiomyopathy. Profibrotic signalling and inter-
stitial collagen deposition are triggered by overproduction
of reactive oxygen and nitrogen species (ROS/RNS) [9]
and/or could be a consequence of apoptotic cardiomyocyte
death (replacement fibrosis). A more pronounced increase in
nitrooxidative stress and apoptosis, along with markedly ele-
vated myocardial content of the profibrotic protein mediator
TGF-𝛽
1
(Figure 5), and significantly higher histopathological
fibrosis score values (Figure 3(d)) have been demonstrated in
type-1 diabetic rats (fibrosis +∼260%)when compared toZDF
rats with type-2DM(fibrosis +∼45%). Although the existence
of myocardial fibrosis in STZ-induced type-1 DM has been
well recognized and widely described [9, 25, 26], there are
controversial data regarding the ZDF type-2 DM model.
Marsh et al. reported no myocardial collagen deposition
in ZDF diabetic animals at 14 weeks of age [27]; other
studies demonstrated only perivascular but not interstitial
myocardial fibrosis [24] at the age of 19 weeks, while a robust
fibrotic remodelling of the left ventricle has been described
in 45-week-old ZDF rats [28]. Differences regarding the age
of the animals and thus different diabetes duration could
be the reason for these discrepancies. Our present results
showing ∼45% increase in myocardial interstitial fibrosis
score in 30–32-week-old ZDF diabetic rats (Figure 3(d)) are
in accordance with these literature data. Interestingly, a much
shorter diabetes duration (8 weeks) leads to a more severe
myocardial fibrosis in the type-1 compared to the type-2 DM
model (30–32 weeks of age corresponds to 23–25 weeks of
diabetes duration). Although the severity of DM (degree of
hyperglycemia) was found to be the same at the end of our
investigations (Table 2), pathophysiological/metabolic differ-
ences (insulinopenia versus hyperinsulinaemia and insulin
resistance in the first phase) and the different time course of
DM between the two types of the disease might explain these
characteristics. In accordance with previous observations
[28] increased fibrosis score values of the Masson’s trichrome
staining in the diabetic myocardium were associated with
depressed mRNA expression of collagens 1 and 3 (Figure 4),
suggesting that altered rate of collagen degradation rather
than enhanced synthesis is responsible for the observed
interstitial fibrosis.
Diabetic cardiomyopathy is associated with changes
in the expression and bioavailability of vasoactive factors
released from the endotheliumof coronarymicrovasculature,
including upregulation of endothelin-1 (ET-1) and down-
regulation of nitric oxide (NO) [29]. In accordance with
these observations we detected a marked increase in the
expression of ET-1 in diabetic heart of both DM models
(more pronounced in type-1DM) alongwith decreased eNOS
expression only in animals with type-1 diabetes (Figure 4).
These results suggest more severe cardiac microvascular
abnormalities in type-1 versus type-2 DM. Increased ET-1
levels in DM have been associated with the development
of myocardial fibrotic remodeling through the accumulation
of fibroblasts, mediated by the ET-1-induced endothelial-to-
mesenchymal transition process [30].This mechanismmight
be reflected by the above discussed corresponding differences
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in the severity of myocardial fibrosis between the two DM
models.
The functional alterations described in the diabetic heart
are closely associated with molecular and histopathologi-
cal evidence of cardiomyocyte hypertrophy, apoptosis, and
fibrosis as discussed above [9].The contributing components
of these three major features to diastolic (heart failure
with preserved ejection fraction, HFPEF) versus systolic
dysfunctionmay be somewhat different. Both cardiomyocyte
hypertrophy and cardiac fibrosis are evident in HFPEF, but
the latter—along with increased cardiomyocyte apoptosis—
is reported to be more prominent in systolic heart failure [9,
17, 18]. In contrast to diabetes-associated HFPEF, myocardial
systolic dysfunction in DM may have a greater reliance
on cardiomyocyte-generated ROS, cardiomyocyte apopto-
sis and subsequent extracellular matrix deposition, and
fibrotic remodelling of the myocardium [17, 31]. Although
not investigated in the present study, additional molec-
ular mechanisms (such as advanced glycation end prod-
ucts (AGE) deposition, collagen cross-linking, and oxidative
modifications of sarcomeric proteins) might also contribute
to the development of diastolic dysfunction in diabetic
animals.
According to the above discussed pathophysiological
changes, our previously published [6] and current results on
in vivo cardiac function (LV P-V analysis, Figure 1) showed
corresponding differences in the characteristics of type-1 and
type-2 diabetic cardiac dysfunction. A marked impairment
of LV contractility and systolic dysfunction (decreased EF
and slope of ESPVR) could be demonstrated only in type-
1 DM, which was accompanied by severe nitrooxidative
stress, cardiomyocyte apoptosis, and myocardial fibrosis.
In contrast to the type-1 DM model, these pathological
features were significantly less pronounced or absent, while
cardiomyocyte hypertrophy was comparable in type-2 DM.
ZDF type-2 diabetic animals showed a marked increase in
diastolic stiffness (increased LVEDP and slope of EDPVR)
without impairment of systolic performance of the heart
(characteristic for HFPEF). We hypothesize that pathophysi-
ological differences in the disease development, severity, and
progression between the two different types of DM could
be the key factors in the observed functional and molecular
characteristics of diabetic cardiomyopathy in type-1 versus
type-2 DM.
5. Conclusions
In the present study we have provided for the first time a
direct comparison of type-1 and type-2 diabetic cardiomy-
opathy in widely used rodent models. We have shown char-
acteristic functional differences between the two models by
LV P-V analysis and revealed the underlying mechanisms: an
altered pattern of key pathophysiological features (nitroox-
idative stress, cardiomyocyte apoptosis and hypertrophy, and
myocardial fibrosis) in the diabetic heart has been observed.
Our current results help to understand the pathomechanisms
of diabetic cardiomyopathy in type-1 and type-2 DM and can
serve as a basis for further experimental research.
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